Abingdon Health PLC (AIM:ABDX) executive chairman Dr Chris Hand talked with Proactive's Stephen Gunnion about the company’s strong first-half performance, recent contract wins and growth outlook in the diagnostics market. Hand explained that Abingdon Health operates as a contract development and manufacturing organisation specialising in lateral flow and rapid diagnostic testing, now offering a full-service, end-to-end solution from product development through to regulatory approval and manufacturing. This expanded “one-stop shop” model is helping differentiate the company in a competitive sector. The company reported a 45% increase in revenue in the first half, with expectations for an even stronger second half. Hand also highlighted two major contract wins, including a $2.5 million international project and a £4.8 million agreement to develop multiplex lateral flow tests. These tests allow multiple biomarkers to be analysed in a single device, moving beyond traditional yes/no diagnostics. As Hand noted, “these tests [are] basically an onsite version of a lab test,” reflecting growing demand from biotech and pharmaceutical customers. The company is also expanding its US presence, with its Madison, Wisconsin, facility supporting increased manufacturing capacity and trading of its shares on the OTCQB to improve investor access and liquidity. Looking ahead, continued contract momentum and revenue growth are expected to drive performance through the second half of the year. For more videos like this, visit Proactive’s YouTube channel, like this video, subscribe, and enable notifications so you never miss an update. #AbingdonHealth #Diagnostics #LateralFlow #Biotech #HealthcareInnovation #RapidTesting #MedTech #Pharma #InvestorNews #SmallCaps #AIMMarket #USExpansion #MultiplexTesting #GrowthStocks